Find the latest clinical trials by condition, location & phase
Browse and search for drug information and related clinical trials
Explore a comprehensive list of organizations, including their profiles and details.
Latest updates on clinical trials, pharmaceuticals, and healthcare companies
Stay informed with timely notifications on clinical trials and research advancements.
No overview information available.
No background information available.
No indication information available.
No associated conditions information available.
Proteolysis-targeting chimeras (PROTACs) represent a revolutionary approach to drug development, capable of degrading previously untreatable disease-causing proteins by targeting proteins without functional active sites.
Bavdegalutamide (ARV-110), a PROTAC androgen receptor degrader, demonstrates potent activity against wild-type and mutant AR in preclinical models.
PROTACs represent a novel therapeutic approach, leveraging the body's ubiquitin-proteasome system to selectively degrade disease-causing proteins.